Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.68 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.68 |
| ▸ | MBTD1 | Q05BQ5 | 2/20 | 0.68 |
| ▸ | L3MBTL3 | Q96JM7 | 2/20 | 0.68 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.65 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | TP53BP1 | Q12888 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6619237 | 0.84 | SLC6A3 (0.66) | SIGMAR1SLC6A3 | |
| SCHEMBL5253698 | 0.82 | SIGMAR1 (0.58) | HRH3L3MBTL1MBTD1L3MBTL3SIGMAR1 | |
| SCHEMBL5253680 | 0.82 | SIGMAR1 (0.60) | HRH3L3MBTL1MBTD1L3MBTL3SIGMAR1 | |
| SCHEMBL23682835 | 0.81 | L3MBTL1 (1.00) | HRH3L3MBTL1MBTD1L3MBTL3SIGMAR1 | |
| SCHEMBL7536460 | 0.79 | SIGMAR1 (1.00) | SIGMAR1SLC6A3CYP1A2CYP3A4 | |
| SCHEMBL6225183 | 0.79 | HRH3 (0.68) | HRH3L3MBTL1MBTD1L3MBTL3SIGMAR1 | |
| SCHEMBL1877934 | 0.79 | HRH3 (0.68) | HRH3L3MBTL1MBTD1L3MBTL3SIGMAR1 | |
| SCHEMBL13958981 | 0.79 | L3MBTL1 (0.96) | HRH3L3MBTL1MBTD1L3MBTL3SIGMAR1 | |
| SCHEMBL23377646 | 0.79 | HRH3 (0.68) | HRH3L3MBTL1MBTD1L3MBTL3SIGMAR1 | |
| SCHEMBL1899856 | 0.79 | HRH3 (0.71) | HRH3L3MBTL1MBTD1L3MBTL3SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7592373-B2 | Amide compounds with MCH antagonistic activity and medicaments comprising these compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-09-22 | — | — | US | disclosed |
| WO-2005063239-A9 | 3-(4-PIPERIDINE-1YLMETHYL-PHENYL)-PROPION ACID-PHENYLAMIDE-DERIVATIVES AND RELATED COMPOUNDS USED IN THE FORM OF MCH ANTAGONISTS (MELANINE CONCENTRATING HORMONE) FOR TREATING EATING DISORDERS | BOEHRINGER INGELHEIM INT (DE) | 2006-03-09 | — | — | WO | disclosed |
| US-20050267093-A1 | Amide compounds with MCH antagonistic activity and medicaments comprising these compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050267093-A1 | Amide compounds with MCH antagonistic activity and medicaments comprising these compounds | MCHR1, MC4R, MCHR2 | HRH3 129/4885L3MBTL1 621/4885MBTD1 167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.